Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19350391 | 0.74 | CDC7 (0.35) | CDC7DBF4BACE1 | |
| SCHEMBL24525785 | 0.66 | CDC7 (0.39) | CDC7DBF4 | |
| SCHEMBL17837194 | 0.65 | CES1 (0.35) | CDC7ROCK1DBF4HTT | |
| SCHEMBL17873725 | 0.65 | CDC7 (0.46) | CDC7ROCK1DBF4BACE1 | |
| SCHEMBL31411707 | 0.64 | PDK2 (0.37) | BACE1 | |
| SCHEMBL30029469 | 0.63 | TGM2 (0.46) | — | |
| SCHEMBL17141573 | 0.63 | TGM2 (0.46) | — | |
| SCHEMBL1476086 | 0.63 | TDP2 (0.46) | — | |
| SCHEMBL17837261 | 0.63 | MAPK3 (0.32) | — | |
| SCHEMBL25348186 | 0.62 | MEN1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12133841-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | JS INNOMED HOLDINGS LTD. (KY) | 2024-11-05 | — | — | US | disclosed |
| US-20240352029-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-10-24 | — | — | US | disclosed |
| WO-2024216249-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-10-17 | — | — | WO | disclosed |
| CN-115504986-B | Apoptosis signal regulating kinase inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024051717-A1 | COMPOUND AS PLK1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海深势唯思科技有限责任公司 | 2024-03-14 | — | — | WO | disclosed |
| CN-117658987-A | Compounds as PLK1 inhibitors, and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112638917-B | Heterocyclic compounds as kinase inhibitors, compositions comprising the same, and methods of use thereof | 捷思英达控股有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-115504986-A | Apoptosis signal regulating kinase inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-111094250-B | Apoptosis signal regulating kinase inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-112457326-B | Aromatic heterocyclic lactam compound, preparation method and application | 上海凌达生物医药有限公司 | 2022-02-15 | — | — | CN | disclosed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| WO-2016106029-A1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106029-A1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106009-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176896-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | CDC7 266/4885ROCK1 520/4885DBF4 3705/4885 |
| US-20240352029-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | CDC7 63/4885ROCK1 781/4885DBF4 2971/4885 |
| US-12133841-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | MAP3K11, MAP3K13, MAP3K1 | CDC7 356/4885ROCK1 276/4885DBF4 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.